APA (7th ed.) Citation

JS, W., T, P., BD, S., LA, S., EX, D., T, W., . . . AN, S. (2023). Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: A propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival. Cancer immunology, immunotherapy : CII, 72(4), 945. https://doi.org/10.1007/s00262-022-03302-5

Chicago Style (17th ed.) Citation

JS, Weber, et al. "Nivolumab Versus Placebo as Adjuvant Therapy for Resected Stage III Melanoma: A Propensity Weighted Indirect Treatment Comparison and Number Needed to Treat Analysis for Recurrence-free Survival and Overall Survival." Cancer Immunology, Immunotherapy : CII 72, no. 4 (2023): 945. https://doi.org/10.1007/s00262-022-03302-5.

MLA (9th ed.) Citation

JS, Weber, et al. "Nivolumab Versus Placebo as Adjuvant Therapy for Resected Stage III Melanoma: A Propensity Weighted Indirect Treatment Comparison and Number Needed to Treat Analysis for Recurrence-free Survival and Overall Survival." Cancer Immunology, Immunotherapy : CII, vol. 72, no. 4, 2023, p. 945, https://doi.org/10.1007/s00262-022-03302-5.